Naderi Sahar, Foody Joanne M
Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Int J Nephrol Renovasc Dis. 2012;5:165-9. doi: 10.2147/IJNRD.S28159. Epub 2012 Dec 20.
The majority of chronic kidney disease patients die of cardiovascular disease prior to reaching end-stage renal disease. The combination of ezetimibe and a statin has been the focus of a number of recent studies, given initial data showing a substantial reduction in low- density lipoprotein with the addition of ezetimibe. However, it is unclear how this low-density lipoprotein reduction impacts cardiovascular disease outcomes. This review will briefly discuss the burden of cardiovascular disease and the pathophysiology of dyslipidemia in chronic kidney disease patients. It will then assess the data regarding the impact of adding ezetimibe to a statin on the general population, and specifically predialysis chronic kidney disease patients.
大多数慢性肾脏病患者在进入终末期肾病之前死于心血管疾病。鉴于初步数据显示添加依折麦布后低密度脂蛋白大幅降低，依折麦布与他汀类药物的联合用药已成为近期多项研究的焦点。然而，尚不清楚这种低密度脂蛋白的降低如何影响心血管疾病的预后。本综述将简要讨论慢性肾脏病患者的心血管疾病负担和血脂异常的病理生理学。然后，它将评估关于在他汀类药物中添加依折麦布对普通人群，特别是透析前慢性肾脏病患者影响的数据。
